Illumina, Inc is a biotechnology firm specializing in the development and marketing of systems for analyzing genetic variation and biological function. Their sequencing systems play a pivotal role in diagnosing genetic diseases, pinpointing cancer mutations, and monitoring treatment outcomes. Additionally, their technologies assist in researching the genetic basis of diseases, drug development, and providing consumers with insights into their genomes.

In 2022, Illumina set up an Excellence Center in Israel, emphasizing the advancement of Artificial Intelligence (AI) for genome analysis. Located in Tel Aviv, this center is dedicated to AI-driven interpretation technology, aiding researchers and clinicians. The primary goal is to offer rapid and insightful interpretations, particularly benefiting the diagnosis of rare diseases, notably affecting children under five.